COVID Supplement NIAID DAIT CLINICAL PRODUCTS CENTER (CPC)

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: ANBU  DEVASAHAYAM
Fiscal Year: 2022
Award: $738,702
Funding agency: National Institute of Allergy and Infectious Diseases

The Clinical Product Center under contract, provides Investigational Product Services for all DAIT-funded and/or sponsored clinical research programs and other NIAID-funded clinical trials as needed. Studies to be supported encompass a broad range of immune-mediated & rare diseases, including: (i) asthma and allergic diseases; (ii) autoimmune disorders; (iii) immune-mediated rejection in solid organ, tissue and cell transplantation; and (iv) (v) Basic Science studies (Opioid Vaccine studies). Additionally, and on an as-needed basis, clinical trials of infectious disease treatment (i.e.SARS-CoV-2), prevention and other vaccine studies. Investigational Products to be studied include schedule I through VI pharmaceutical agents, biologics, foods as study interventions, and other agents.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Allergic Disease><Asthma><Autoimmune Diseases><Basic Research><Basic Science><Biologic Products><Biological Agent><Biological Products><Bronchial Asthma><COVID><COVID-19 virus><COVID19 virus><Cell Transplantation><Clinical><Clinical Research><Clinical Study><Clinical Trials><CoV disease><CoV-2><CoV2><Conduct Clinical Trials><Contracting Opportunities><Contracts><Coronaviridae><Coronavirus><Disease><Disorder><Food><Food or Food Product><Funding><Grafting Procedure><Immune><Immunes><Intervention Studies><Investigation><Mediating><NIAID><National Institute of Allergy and Infectious Disease><Opiates><Opioid><Organ Transplantation><Organ Transplants><Orphan Disease><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Prevention><Rare Diseases><Rare Disorder><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Schedule><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Solid><Tissue Transplantation><Wuhan coronavirus><autoimmune condition><autoimmune disorder><biologics><biopharmaceutical><biotherapeutic agent><corona virus><corona virus disease><coronavirus disease><coronavirus disease 2019 virus><coronavirus disease-19 virus><hCoV19><infectious disease treatment><intervention research><interventional research><interventional study><interventions research><nCoV2><organ allograft><organ graft><organ xenograft><orphan disorder><programs><vaccination study><vaccination trial><vaccine study><vaccine trial>